TrialPath
Recruiting

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

NCT07659795 · Verastem, Inc.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)
About this study
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
Eligibility criteria
Inclusion Criteria: * Histopathology confirmed metastatic CRC * Measurable disease per RECIST 1.1 * Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing) * ECOG PS=0 or 1 2L+ patients: * Must have received at least 1 standard chemotherapy for metastatic colorectal adenocarcinoma * Have documented disease progression during or following their most recent prior line of therapy * Have either stable disease, partial response (PR), or complete response (CR) by RECIST v1.1 as the best overall response (BOR) during at least 1 prior systemic therapy. 1L patients: * Treatment-naïve or received no more than 1 cycle of standard systemic therapy for metastatic disease. Exclusion Criteria: * Have any other documented co-existing common RAS mutation(s) * Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter * Major surgery within 4 weeks of first treatment dose * Radiation therapy (RT) within 1 week of first treatment dose * Receipt of prior direct RAS inhibitor * Receipt of more than 1 investigational therapy * Untreated or symptomatic CNS metastasis * Receipt of strong CYP3A4 inhibitor/inducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter * Receipt of PPI or H2 blocker within 5 days * Inability to swallow oral medication * Other protocol-defined inclusion/exclusion criteria may apply
Study design
Enrollment target: 150 participants
Allocation: randomized
Masking: single
Age groups: adult, older_adult
Timeline
Starts: 2026-07-28
Estimated completion: 2028-12
Last updated: 2026-11-19
Interventions
Drug: VS-7375Drug: cetuximabDrug: panitumumabDrug: Cetuximab + mFOLFOX6
Primary outcomes
  • • Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only (6 months)
  • • To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab or panitumumab, administered on a daily oral schedule in participants with KRAS G12D-mutated 2L+ CRC (6 months)
  • • To characterize the safety and tolerability of VS-7375 in combination with cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated 1L CRC (6 months)
Sponsor
Verastem, Inc. · industry
Contacts & investigators
ContactVerastem Call Center · contact · VS-7375-203TrialSupport@verastem.com · 7812924204
ContactBina Tejura, MD · contact · VS-7375-203Medical@verastem.com
All locations (35)
HonorHealthRecruiting
Scottsdale, Arizona, United States
START Los AngelesRecruiting
Los Angeles, California, United States
Cedars-Sinai Medical CenterRecruiting
Los Angeles, California, United States
Valkyrie Clinical Trials (contact for more locations)Recruiting
Los Angeles, California, United States
BRCR - Coral SpringsRecruiting
Coral Springs, Florida, United States
BRCR - TamaracRecruiting
Tamarac, Florida, United States
Moffitt Cancer CenterRecruiting
Tampa, Florida, United States
Indiana University, Simon Comprehensive Cancer CenterRecruiting
Indianapolis, Indiana, United States
University of MichiganRecruiting
Ann Arbor, Michigan, United States
START MidwestRecruiting
Grand Rapids, Michigan, United States
Washington UniversityRecruiting
St Louis, Missouri, United States
START New JerseyRecruiting
East Brunswick, New Jersey, United States
Perlmutter Cancer Center at NYU Langone Health (contact for more locations)Recruiting
New York, New York, United States
University of North CarolinaRecruiting
Chapel Hill, North Carolina, United States
Case Western, University Hospitals Cleveland Medical CenterRecruiting
Cleveland, Ohio, United States
Sarah Cannon Research Institute Oncology PartnersRecruiting
Nashville, Tennessee, United States
START Dallas Fort WorthRecruiting
Fort Worth, Texas, United States
The University of Texas MD Anderson Cancer CenterRecruiting
Houston, Texas, United States
Huntsman Cancer Institute - University of UtahRecruiting
Salt Lake City, Utah, United States
START Mountain RegionRecruiting
West Valley City, Utah, United States
UVA Comprehensive Cancer CenterRecruiting
Charlottesville, Virginia, United States
Virginia Cancer SpecialistsRecruiting
Fairfax, Virginia, United States
Virginia Mason Medical CenterRecruiting
Seattle, Washington, United States
University of WisconsinRecruiting
Madison, Wisconsin, United States
Macquarie University HospitalRecruiting
Macquarie Park, New South Wales, Australia
Calvary Mater NewcastleRecruiting
Waratah, New South Wales, Australia
Icon Cancer Centre TownsvilleRecruiting
Hyde Park, Queensland, Australia
Icon Cancer Centre South BrisbaneRecruiting
South Brisbane, Queensland, Australia
Icon Cancer Centre AdelaideRecruiting
Kurralta Park, South Australia, Australia
Icon Cancer Centre HobartRecruiting
Hobart, Tasmania, Australia
Alfred HospitalRecruiting
Melbourne, Victoria, Australia
CHU UCL Namur Site St. ElisabethRecruiting
Namur, Belgium
Centre Georges François LeclercRecruiting
Dijon, France, France
Hospital Universitario Ramón y CajalRecruiting
Madrid, Spain, Spain
START Barcelona - HM Nou DelfosRecruiting
Barcelona, Spain